Intrinsiqs

Is BridgeBio Oncology Therapeutics Inc. overvalued?

BridgeBio Oncology Therapeutics Inc. (BBOT) — key valuation metrics and fundamentals.

No verdict
Price
$2.14
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$171.6M
Dividend yield
0.0%
Return on equity
-49.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares BBOT's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.